 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
48 News |  |
- | nelotanserin (RVT-102) / Roivant
Preclinical, Journal: Nelotanserin, a selective 5-HT2A receptor inverse agonist, attenuates aspects of nicotine withdrawal but not reward in mice. (Pubmed Central) - May 6, 2024
However, nelotanserin had no effect on anxiety-like behavior and failed to reduce nicotine reward as measured in the conditioned place preference test. Our results suggest that inverse agonism of the 5-HT2A receptor may be a feasible novel mechanism for smoking cessation by reducing both physical withdrawal and thermal hyperalgesia associated with nicotine abstinence but may require complementary pharmacotherapies targeting affective and reward-associated decrements to improve cessation outcomes.
- | nelotanserin (RVT-102) / Roivant, Nuplazid (pimavanserin) / Acadia Pharma
Journal: Ligand bias and inverse agonism on 5-HT2A receptor-mediated modulation of G protein activity in post-mortem human brain. (Pubmed Central) - Apr 22, 2024
The results reveal the existence of constitutively active 5-HT2A receptors in human pre-frontal cortex and demonstrate different pharmacological profiles of various 5-HT2A receptor drugs previously considered antagonists. These findings indicate that altanserin and pimavanserin possess biased inverse agonist profile towards 5-HT2A receptor activation of Gi1 proteins.
- nelotanserin (RVT-102) / Roivant
Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1488;
These findings indicate that altanserin and pimavanserin possess biased inverse agonist profile towards 5-HT2A receptor activation of Gi1 proteins. These results provide incremental pre-clinical evidence that 5-HT antagonism is an efficacious anti-dyskinetic approach.
- || Review, Journal: Lewy Body Dementia: An Overview of Promising Therapeutics. (Pubmed Central) - Aug 12, 2023
Of symptomatic therapies for psychosis recently investigated, pimavanserin shows promise in LBD, but studies of nelotanserin have been suspended. Although the discovery of novel symptomatic and disease-modifying therapeutics remains a significant challenge, recently published and upcoming trials signify promising strides toward that aim.
- | nelotanserin (RVT-102) / Roivant
Journal: The 5-HT inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset. (Pubmed Central) - Jul 29, 2023
Nelotanserin had no impact on the anti-parkinsonian action of L-DOPA. Our results highlight that nelotanserin may represent an efficacious anti-dyskinetic drug and provide incremental evidence of the potential benefit of 5-HT antagonism/inverse agonism for drug-induced dyskinesia in PD.
- | Journal: An overview of the active clinical trials for Parkinson's disease psychosis. (Pubmed Central) - Jul 9, 2022
Tweetable abstract An overview of the active clinical trials for Parkinson's disease psychosis. In this article, we review the drugs currently undergoing clinical testing for Parkinson's disease psychosis and offer some perspectives on the treatment of the condition.
- || nelotanserin (RVT-102) / Roivant
Clinical, Journal, Video: Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia. (Pubmed Central) - Jul 7, 2021
P2
Despite negative results, this is the first randomized, placebo-controlled study on symptomatic RBD treatment using objective outcome measures based on systematic video analysis. This study provides a new method for outcome research in RBD and proves that movement analysis is a feasible and meaningful outcome for studies evaluating changes in RBD severity.
- nelotanserin (RVT-102) / Roivant
[VIRTUAL] A double-blind randomized study with video analysis evaluating Nelotanserin as symptomatic treatment for RBD in DLB/ PDD (Main Auditorium) - May 30, 2021 - Abstract #EAN2021EAN_1788;
Despite negative results, this is the 1st randomized, placebo-controlled study on symptomatic RBD treatment using objective outcome measures based on systematic video analysis. This study provides a new method for outcome research in RBD and proves that movement analysis is a feasible and meaningful outcome for studies evaluating changes in RBD severity.
- | nelotanserin (RVT-102) / Roivant, Nuplazid (pimavanserin) / Acadia Pharma
Journal: Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [35S]GTPĪ³S Binding Assays. (Pubmed Central) - Sep 27, 2020
Our results demonstrate that some of these drugs, previously described as serotonin 5-HT2A receptor agonists, antagonists or inverse agonists, are not so specific and show different intrinsic activity to that previously reported. Overall, this work opens a new gate for the prediction of GPCRs targeting compounds.
- nelotanserin (RVT-102) / Roivant, Nuplazid (pimavanserin) / Acadia Pharma
[VIRTUAL] Functional selectivity of different serotonin 5-HT2A receptor antagonists in human post-mortem brain cortex (Poster Area) - Aug 5, 2020 - Abstract #ECNP2020ECNP_915;
These findings also demonstrate that altanserin and pimavanserin display preferential inverse agonist effect on 5-HT2AR coupling to Gai1-proteins, with no effect on Gaq/11-proteins. If the hypothesis of an increase in 5-HT2AR pre-coupling to Gai1-proteins in schizophrenia was finally demonstrated, these two drugs would be a good starting point to develop a new generation of antipsychotic drugs, with potential improved efficacy and, perhaps, a lower adverse effect profile.
- nelotanserin (RVT-102) / Roivant, Nuplazid (pimavanserin) / Acadia Pharma
[VIRTUAL] Functional selectivity of different serotonin 5-HT2A receptor antagonists in human post-mortem brain cortex (Room 2) - Jul 10, 2020 - Abstract #ECNP2020ECNP_226;
These findings also demonstrate that altanserin and pimavanserin display preferential inhibition of 5-HT2A R coupling to Ga i1 -proteins vs canonical Ga q/11 -proteins. The information about functional selectivity in native tissue will help to develop new generation of antipsycothics, considering that the Ga i1 -protein pathway has been implicated in schizophrenia.
- ||||| nelotanserin (RVT-102) / Roivant
Trial completion date, Trial termination, Trial primary completion date: Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder (clinicaltrials.gov) - Mar 27, 2019
P2, N=80, Terminated, Sponsor: Axovant Sciences Ltd.
The information about functional selectivity in native tissue will help to develop new generation of antipsycothics, considering that the Ga i1 -protein pathway has been implicated in schizophrenia. Trial completion date: Jul 2019 --> Jan 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Jan 2019; Changes to the overall development program for the study medication
- | nelotanserin (RVT-102) / Roivant
Trial completion, P2 data, Trial completion date, Trial primary completion date: Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) (clinicaltrials.gov) - Oct 23, 2018
P2, N=29, Completed, Sponsor: Axovant Sciences Ltd.
Trial completion date: Jul 2019 --> Jan 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Jan 2019; Changes to the overall development program for the study medication Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2018 | Trial primary completion date: Aug 2018 --> May 2018
- | nelotanserin (RVT-102) / Roivant
Enrollment closed: Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder (clinicaltrials.gov) - Oct 23, 2018
P2, N=80, Active, not recruiting, Sponsor: Axovant Sciences Ltd.
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2018 | Trial primary completion date: Aug 2018 --> May 2018 Enrolling by invitation --> Active, not recruiting
- | nelotanserin (RVT-102) / Roivant
Enrollment closed, P2 data, Enrollment change, Trial completion date, Trial primary completion date: Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) (clinicaltrials.gov) - Feb 14, 2018
P2, N=29, Active, not recruiting, Sponsor: Axovant Sciences Ltd.
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | N=60 --> 29 | Trial primary completion date: Mar 2018 --> Aug 2018 | Trial completion date: Mar 2018 --> Aug 2018
- || nelotanserin (RVT-102) / Roivant
Trial completion date, Trial primary completion date: Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder (clinicaltrials.gov) - Feb 14, 2018
P2, N=80, Enrolling by invitation, Sponsor: Axovant Sciences Ltd.
Recruiting --> Active, not recruiting | N=60 --> 29 | Trial primary completion date: Mar 2018 --> Aug 2018 | Trial completion date: Mar 2018 --> Aug 2018 Trial primary completion date: Jul 2018 --> Jul 2019 | Trial completion date: Jul 2018 --> Jul 2019
- | nelotanserin (RVT-102) / Roivant
Trial completion, Enrollment change: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Dec 14, 2017
P2, N=30, Completed, Sponsor: Axovant Sciences Ltd.
Trial primary completion date: Jul 2018 --> Jul 2019 | Trial completion date: Jul 2018 --> Jul 2019 Active, not recruiting --> Completed | N=20 --> 30
- || nelotanserin (RVT-102) / Roivant
P2 data, Trial primary completion date: Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) (clinicaltrials.gov) - Oct 9, 2017
P2, N=60, Recruiting, Sponsor: Axovant Sciences Ltd.
Active, not recruiting --> Completed | N=20 --> 30 Trial primary completion date: Sep 2017 --> Mar 2018
- nelotanserin (RVT-102) / Roivant
Trial primary completion date: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Oct 9, 2017
P2, N=20, Active, not recruiting, Sponsor: Axovant Sciences Ltd.
Trial primary completion date: Sep 2017 --> Mar 2018 Trial primary completion date: Sep 2017 --> Dec 2017
- | nelotanserin (RVT-102) / Roivant
Enrollment closed: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Aug 10, 2017
P2, N=20, Active, not recruiting, Sponsor: Axovant Sciences Ltd.
Trial primary completion date: Sep 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- || nelotanserin (RVT-102) / Roivant
P2 data, Trial primary completion date: Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) (clinicaltrials.gov) - Jul 2, 2017
P2, N=60, Recruiting, Sponsor: Axovant Sciences Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Sep 2017
- nelotanserin (RVT-102) / Roivant
Trial primary completion date: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Jul 2, 2017
P2, N=20, Recruiting, Sponsor: Axovant Sciences Ltd.
Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: May 2017 --> Sep 2017
- nelotanserin (RVT-102) / Roivant
Trial primary completion date: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Jan 9, 2017
P2, N=20, Recruiting, Sponsor: Axovant Sciences Ltd.
Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Dec 2016 --> May 2017
- ||||| nelotanserin (RVT-102) / Roivant
New P2 trial: Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder (clinicaltrials.gov) - Aug 19, 2016
P2, N=80, Enrolling by invitation, Sponsor: Axovant Sciences Ltd.
- ||||| nelotanserin (RVT-102) / Roivant
New P2 trial, P2 data: Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) (clinicaltrials.gov) - Mar 15, 2016
P2, N=60, Recruiting, Sponsor: Axovant Sciences Ltd.
- | nelotanserin (RVT-102) / Roivant
Enrollment open: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Jan 28, 2016
P2, N=20, Recruiting, Sponsor: Axovant Sciences Ltd.
Trial primary completion date: Dec 2016 --> May 2017 Not yet recruiting --> Recruiting
- | nelotanserin (RVT-102) / Roivant
New P2 trial: Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia (clinicaltrials.gov) - Dec 29, 2015
P2, N=20, Not yet recruiting, Sponsor: Axovant Sciences Ltd.